PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24957319-0	2014	Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.	gemcitabine	114-125	prokineticin 2	Mus musculus	5-8	
24957319-5	2014	Furthermore, Bv8 is highly expressed in MDSCs colonizing pancreatic tumors in mice treated with weekly gemcitabine compared to MC gemcitabine or the combination of the two regimens.	gemcitabine	103-114	prokineticin 2	Mus musculus	13-16	
24957319-6	2014	Blocking Bv8 with antibodies in weekly gemcitabine-treated mice results in a significant reduction in tumor regrowth, angiogenesis, and metastasis.	gemcitabine	39-50	prokineticin 2	Mus musculus	9-12	
24957319-7	2014	Overall, our results suggest that pro-tumorigenic effects induced by weekly gemcitabine are mediated in part by MDSCs expressing Bv8.	gemcitabine	76-87	prokineticin 2	Mus musculus	129-132	
24957319-8	2014	Therefore, both Bv8 inhibition and MC can be used as legitimate "add-on" treatments for preventing post-chemotherapy pancreatic cancer recurrence, progression, and metastasis following weekly gemcitabine therapy.	gemcitabine	192-203	prokineticin 2	Mus musculus	16-19